In the BioHarmony Drug Report Database
Promacta, Revolade (eltrombopag olamine) is a small molecule pharmaceutical. Eltrombopag olamine was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic. Promacta’s patents are valid until 2027-08-01 (FDA).
Image (chem structure or protein)